Figure 6.

JAK–STAT signaling is differentially activated in tumor and non-tumor cells in response to various immunotherapies. (A–D) Wild-type (WT) B6 or IFNAR1^−/− mice (n = 5/group) were subcutaneously injected with 5 × 10⁵ B16/OVA cells and their derivatives; starting 8 days later, tumors were injected with 5 μg IFN-α (A–C) or 25 μg anti-PD-L1 antibody (D) or control antibody twice a week. Tumor volume was also measured twice a week. Data are presented as the mean ± SEM. ^*P < 0.05 vs. B16-OVA GeCKO-#9 control group; ^**P < 0.01 vs. B16-OVA GeCKO-#9 control group (B); ^**P < 0.01 vs. B16-OVA control group; ^#P < 0.05 vs. B16/OVA-GeCKO-#9 control group; ^##P < 0.01 vs. B16/OVA-GeCKO-#9 control group; (A,D).